Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We investigated whether vaccination of healthy HIV-seronegative and HIV-1-seropositive antiretroviral therapy-treated subjects with recombinant modified vaccinia virus Ankara expressing an HIV-1 immunogen (MVA.HIVA) induced MVA-specific T cell responses. Using IFN-γ Elispot assays, we observed new or increased responses to MVA virus in 52% of HIV-seronegative subjects and 93% HIV-1 seropositive subjects; MVA-specific T cell frequencies were generally low and correlated poorly with T cell responses to the HIV-1 immunogen. In two vaccinees, responses were mapped to CD8+ T cell epitopes present in replication-competent vaccinia virus. These data support further evaluation of MVA as a viral vector for HIV-1 immunogens.

Original publication

DOI

10.1016/j.vaccine.2010.08.077

Type

Journal article

Journal

Vaccine

Publication Date

21/10/2010

Volume

28

Pages

7306 - 7312

Keywords

AIDS Vaccines, Adolescent, Adult, Antiretroviral Therapy, Highly Active, Epitopes, T-Lymphocyte, Genetic Vectors, HIV Infections, HIV Seronegativity, HIV-1, Humans, Immunity, Cellular, Immunization, Secondary, Interferon-gamma, Middle Aged, T-Lymphocytes, Vaccinia virus, Young Adult